Quarterly Result22 May 2025, 05:21 pm
Kilitch Drugs Q4FY25 PAT Surges 212% YoY, Revenue Rises 44% on Standalone Basis
AI Summary
Kilitch Drugs Limited, a leading pharmaceutical company, announced its Q4FY25 financial results. The company reported a 178% Y-o-Y rise in consolidated PAT to Rs. 1,021.86 lakh and a 37% Y-o-Y growth in consolidated revenue from operations to Rs. 6,122.58 lakh. Standalone PAT rose by 212% and revenue grew by 44% to Rs. 1,137.41 lakh and Rs. 18,158.73 lakh, respectively. The company's net profit for FY25 increased by 77% to Rs. 3,115.69 lakh. Kilitch Drugs is a global innovator in pharmaceuticals, with manufacturing units in Mumbai, Ethiopia, and a new green field project in Pen, Maharashtra.
Key Highlights
- Q4FY25 consolidated PAT surged by 178% to Rs. 1,021.86 lakh
- Standalone PAT for Q4FY25 increased by 212% to Rs. 1,137.41 lakh
- Consolidated revenue from operations for Q4FY25 rose by 37% to Rs. 6,122.58 lakh
- Standalone revenue for Q4FY25 grew by 44% to Rs. 18,158.73 lakh
- FY25 standalone net profit increased by 77% to Rs. 3,115.69 lakh